Fig. 3: Summary of arginylation sites and ATE1 substrates in human proteins and proteomes.
From: An unbiased proteomic platform for ATE1-based arginylation profiling
a, Experimental workflow for CALR arginylation. b, Numbers of identified MS1 pairs, arginylation sites, unique peptides and unique proteins in human cells and patient tissues. c, Overview of arginylation sites in human cells and patient tissues. d, Ratio plot of all MS1 pairs detected in all sample fractions. e, Sequence logo calculated from unmodified forms of all unique arginylated peptides. Frequency plots are generated by WebLogo. The arrow indicates the cleavage site before arginylation. f, Arginylation type comparison of all unique sites. g, Biological function analysis of ATE1–protein substrates using PANTHER. iPS, induced pluripotent stem. CF, cardiac fibroblasts. CM, cardiomyocytes. R, arginylation. R_deami, N/Q arginylation after deamidation. PD, Parkinson’s disease. PDD, Parkinson’s disease with dementia. AD, Alzheimer’s disease.
